
Overview
Bioton is a Polish biotechnology company that specializes in the development and production of biopharmaceuticals, particularly insulin for diabetes treatment. They provide a platform for patients to receive expert education and support regarding diabetes management. Their modern factory in Macierzysz, near Warsaw, is equipped with advanced technology for the synthesis and production of insulin.
Financials
Revenue history (in m)
Filing timeliness
Financial statements were filed on time, on average 33 days early. All were audited by a statutory auditor.
- 202529/06/2026
- 202427/06/2025
- 202317/06/2024
- 202222/06/2023
- 202107/07/2022
- 202001/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Sanctions and PEP lists
| Person | List | Match | |
|---|---|---|---|
| Beata Anna Stelmach | Członek organu spółki Skarbu Państwa | confirmed | |
| Waldemar Piotr Dąbrowski | Minister kultury i dziedzictwa narodowego | confirmed | |
| Wiesław Waldemar Walendziak | Poseł na Sejm Rzeczypospolitej Polskiej | confirmed | |
| Wojciech Michał Raduchowski-Brochwicz | Członek organu spółki Skarbu Państwa | confirmed |
Stock quotes
- Open
- PLN 3.44
- High
- PLN 3.46
- Low
- PLN 3.41
- Volume
- 61.66K
- Avg. vol.
- 19.03K
- Market cap
- PLN 295.8M
- P/E ratio
- –
- EPS
- -PLN 26.82
- Shares outstanding
- 85.86M
- 52-week
- PLN 3.34 – 3.54
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLBIOTN00029
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q3 2026 | USD 17.53m | USD 2.07m | USD 280.39k |
| Q2 2026 | USD 19.19m | USD -2.80m | USD -2.48m |
| Q1 2026 | USD 13.27m | USD -1.09m | USD -1.39m |
| Q4 2025 | USD 16.17m | USD 967.86k | USD 442.49k |
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Insulin
- Antidiabetic medicines
- Medical devices
- Injection systems
- Diabetes care solutions
Websites
The sites are available in: Polish and English.
- bioton.comBIOTON – dostawca kompletnych rozwiązań diabetologicznychWordPressGoogle Tag ManagerYoast SEONginx
- biotonweb.plBIOTON – dostawca kompleksowych rozwiązań dla badań nad cukrzycą – rozwiązania dla biotechnologicznego procesu produkcji leków, od DNA po gotowy produkt leczniczyWordPress 7.1Elementor
Trademarks
The company holds 77 active trademarks registered with the Polish Patent Office. 35 marks have expired or were not registered. The first mark was filed in 1993.
| Mark | Protected until | |
|---|---|---|
| Gensucare v (word) | Dec 2, 2031 | |
| Combodiab (word) | Jul 30, 2029 | |
| Depediab (word) | Jul 30, 2029 | |
| BIOTON | Apr 3, 2028 | |
| GensuFine (word) | Aug 3, 2027 |
Job offers
The company has its own careers page: bioton.com/kariera.
Authorized Representatives
Manner of representation
If the management board is a one-person management board, the company is represented by one member of the management board. If the management board is a multi-member management board, the company is represented by two members of the management board acting jointly or one member of the management board acting jointly with a commercial proxy.
Supervisory board
Beneficial owners
Bioton is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.
Capital group
| Name | Ownership |
|---|---|
Informacje ogólne o Biolek Sp. z o.o. | 10% |
PODSTAWOWE INFORMACJE DOTYCZĄCE SPÓŁKI ORAZ GRUPY KAPITAŁOWEJ BIOTON S.A. | 9% |
Skład Zarządu i Rady Nadzorczej Bioton S.A. | 9% |
Bank accounts
Registered as a VAT taxpayer on 1993-07-05.
43 1050 1025 1000 0090 8127 9771
20 1600 1462 1749 1748 0000 0021
88 1050 1025 1000 0024 1417 0395
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 28, 2026 | Call to creditors |
Public aid
10 public aid cases recorded, with a total value of $9,080,083.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 25, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Towarzystwo Inwestycji Społeczno-Ekonomicznych S.A. | |
| Dec 23, 2024 | Aid to cover additional costs related to an exceptionally significant increase in natural gas and electricity prices as a result of the war in Ukraine | –– | Prezes Zarządu Narodowego Funduszu Ochrony Środowiska i Gospodarki Wodnej | |
| Mar 21, 2024 | Aid to cover additional costs related to an exceptionally significant increase in natural gas and electricity prices as a result of the war in Ukraine | –– | Prezes Zarządu Narodowego Funduszu Ochrony Środowiska i Gospodarki Wodnej |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-08-24 | Development of an innovative technology for producing short- and long-acting insulin analogues for use in diabetes therapy. | $5.3M$5,322,824 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Fresenius Kabi Polska sp. z o.o. | $247,097,438.47 | fresenius-kabi.com | ||
| Zentiva Polska sp. z o.o. | $134,295,523.17 | zentiva.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne Polfa S.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| Przedsiębiorstwo Farmaceutyczne Lek-Am sp. z o.o. | $102,266,019.67 | lekam.pl | ||
| Teva Pharmaceuticals Polska sp. z o.o. | $97,284,137.57 | teva.pl | ||
| Sandoz Polska sp. z o.o. | $89,136,265.74 | sandoz.com | ||
| Synoptis Pharma sp. z o.o. | $79,311,000.88 | synoptispharma.pl | ||
| Polfarmex S.A. | $73,543,379.32 | polfarmex.pl | ||
| Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss Biomed S.A. | $40,633,950.51 | biomed.pl | ||
| Reig Jofre sp. z o.o. | $16,662,733.82 | reigjofre.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-08-21 | Share capital reduction (1,717,284,000.00 PLN → 8,586,420.00 PLN) | |
| 2026-07-21 | PKD change (Removed: 72.11.Z, 72.19.Z, 86.90.E; Added: 32.50.B, 72.10.Z, 86.99.D) | |
| 2026-04-27 | Address change (Starościńska 5, 02-516, Warszawa → Ul. Poznańska 12, 05-850, Macierzysz) | |
| 2019-11-25 | PKD change (Removed: 85.60.Z; Added: 72.11.Z) | |
| 2015-07-09 | PKD change (Removed: 43 codes) |
FAQ
Last updated: 2026-10-03